10/665,528

STN - STRUCTURE SEARCH
5-7-04

=> d ibib abs hitstr 1-4

Inventor

L11 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2004:246964 CAPLUS
DOCUMENT NUMBER: 140:287382
TITLE: A preparation of (hetero)cyclic calcium-activated potassium channel activators useful for treatment of, e.g., **pollakiuria** and urinary
INVENTOR(S): Kono, Rikako; Kohnomi, Shuntarou; Aihara, Hajime; Hosaka, Toshihiro; Kashiwagi, Toshihiko
PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 26 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1400243	A1	20040324	EP 2003-255860	20030918

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

PRIORITY APPLN. INFO.: JP 2002-272662 A 20020919
JP 2003-70298 A 20030314
JP 2003-278699 A 20030724

GI



I

AB The invention relates to a preparation of (hetero)cyclic compds. of formula I [wherein: A = benzene, pyridine, cycloalkane; Q = (un)substituted imidazole, oxazole, cyclopentane, pyrrole, or pyridine, etc.; R1 = halogen, aminosulfonyl, alkylsulfonyl, alkanoylaminosulfonyl; R2 = H or halogen; R3, R4 = H, halogen, alkyl, alkoxy; rings A and Q may be fused to each other], useful as large-conductance calcium-activated potassium channel openers. Compds. I have excellent large conductance Ca-activated K-channel opening activity, and are useful for the treatment of hypertension, premature birth, **pollakiuria**, and **urinary incontinence**, etc. Compds. I (prepns. referenced, phys. data for 27 compds.) were tested for a relaxation effect on potassium-induced contraction of isolated rabbit urinary bladder and inhibitory effect on the rhythmic bladder contractions induced by substance P in anesthetized rats.

IT **170569-86-5P**, 4-[5-(4-Chlorophenyl)-3-trifluoromethyl-1H-pyrazol-1-yl]benzenesulfonamide **170569-87-6P**, 4-(5-Phenyl-3-

trifluoromethyl-1H-pyrazol-1-yl)benzenesulfonamide **170569-88-7P**, 4-[5-(4-Fluorophenyl)-3-trifluoromethyl-1H-pyrazol-1-yl]benzenesulfonamide **170569-91-2P**, 4-[5-(4-Methoxyphenyl)-3-trifluoromethyl-1H-pyrazol-1-yl]benzenesulfonamide **170569-95-6P**, 4-[5-(3-Chlorophenyl)-3-trifluoromethyl-1H-pyrazol-1-yl]benzenesulfonamide **170569-96-7P**, 4-[5-(2-Chlorophenyl)-3-trifluoromethyl-1H-pyrazol-1-yl]benzenesulfonamide **170569-97-8P**, 4-[5-(2-Fluorophenyl)-3-trifluoromethyl-1H-pyrazol-1-yl]benzenesulfonamide **170569-99-0P**, 4-[5-(2-Methylphenyl)-3-trifluoromethyl-1H-pyrazol-1-yl]benzenesulfonamide **170570-01-1P**, 4-[5-(3-Methylphenyl)-3-trifluoromethyl-1H-pyrazol-1-yl]benzenesulfonamide **170570-04-4P**, 4-[5-(3-Fluorophenyl)-3-trifluoromethyl-1H-pyrazol-1-yl]benzenesulfonamide **170570-10-2P**, 4-[5-(2-Methoxyphenyl)-3-trifluoromethyl-1H-pyrazol-1-yl]benzenesulfonamide **170570-14-6P**, 4-[5-(3,4-Dimethoxyphenyl)-3-trifluoromethyl-1H-pyrazol-1-yl]benzenesulfonamide **181696-14-0P**, 4-[5-Methyl-3-(4-bromophenyl)isoxazol-4-yl]benzenesulfonamide **198471-47-5P**, N-Acetyl-4-[5-(4-methylphenyl)-3-trifluoromethyl-1H-pyrazol-1-yl]benzenesulfonamide **477801-65-3P**, 4-[5-(3-Methoxyphenyl)-3-trifluoromethyl-1H-pyrazol-1-yl]benzenesulfonamide **499206-50-7P**, 4-[5-(4-Methylphenyl)-3-methyl-1H-pyrazol-1-yl]benzenesulfonamide **569362-58-9P**, 4-[5-(3,4-Dimethylphenyl)-3-trifluoromethyl-1H-pyrazol-1-yl]benzenesulfonamide **675605-68-2P**, 4-[5-(4-Methylphenyl)-3-chloromethyl-1H-pyrazol-1-yl]benzenesulfonamide **675605-69-3P**, 4-[5-(4-Methylphenyl)-3-n-propyl-1H-pyrazol-1-yl]benzenesulfonamide **675605-70-6P**, 4-[5-(4-Methylphenyl)-3-ethyl-1H-pyrazol-1-yl]benzenesulfonamide **675605-71-7P**, 4-[5-(4-Methylphenyl)-3-isopropyl-1H-pyrazol-1-yl]benzenesulfonamide **675605-72-8P**, 5-(4-Methylphenyl)-1-(4-methylsulfonylphenyl)-3-trifluoromethyl-1H-pyrazole
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of (hetero)cyclic compds. useful as calcium-activated potassium channel openers/activators)

RN 170569-86-5 CAPLUS
CN Benzenesulfonamide, 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RN 170569-87-6 CAPLUS
CN Benzenesulfonamide, 4-[5-phenyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RN 170569-88-7 CAPLUS
CN Benzenesulfonamide, 4-[5-(4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RN 170569-91-2 CAPLUS
CN Benzenesulfonamide, 4-[5-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RN 170569-95-6 CAPLUS
CN Benzenesulfonamide, 4-[5-(3-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RN 170569-96-7 CAPLUS
CN Benzenesulfonamide, 4-[5-(2-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RN 170569-97-8 CAPLUS
CN Benzenesulfonamide, 4-[5-(2-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RN 170569-99-0 CAPLUS
CN Benzenesulfonamide, 4-[5-(2-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-

yl]- (9CI) (CA INDEX NAME)



RN 170570-01-1 CAPLUS
CN Benzenesulfonamide, 4-[5-(3-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RN 170570-04-4 CAPLUS
CN Benzenesulfonamide, 4-[5-(3-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RN 170570-10-2 CAPLUS
CN Benzenesulfonamide, 4-[5-(2-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RN 170570-14-6 CAPLUS
CN Benzenesulfonamide, 4-[5-(3,4-dimethoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RN 181696-14-0 CAPLUS
CN Benzenesulfonamide, 4-[3-(4-bromophenyl)-5-methyl-4-isoxazolyl]- (9CI) (CA INDEX NAME)



RN 198471-47-5 CAPLUS
CN Acetamide, N-[[4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 477801-65-3 CAPLUS
CN Benzenesulfonamide, 4-[5-(3-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RN 499206-50-7 CAPLUS
CN Benzenesulfonamide, 4-[3-methyl-5-(4-methylphenyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RN 569362-58-9 CAPLUS
CN Benzenesulfonamide, 4-[5-(3,4-dimethylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RN 675605-68-2 CAPLUS
CN Benzenesulfonamide, 4-[3-(chloromethyl)-5-(4-methylphenyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RN 675605-69-3 CAPLUS
CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-propyl-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RN 675605-70-6 CAPLUS
CN Benzenesulfonamide, 4-[3-ethyl-5-(4-methylphenyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RN 675605-71-7 CAPLUS
CN Benzenesulfonamide, 4-[3-(1-methylethyl)-5-(4-methylphenyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RN 675605-72-8 CAPLUS
CN 1H-Pyrazole, 5-(4-methylphenyl)-1-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



IT **93014-16-5,** 4-(2-Methyl-4-phenyloxazol-5-yl)benzenesulfonamide
169590-42-5, Celecoxib **180200-68-4,** Tilmacoxib
181695-72-7, Valdecoxib **198470-84-7,** Parecoxib
265114-23-6, 4-[4-Chloro-5-(3-fluoro-4-methoxyphenyl)imidazol-1-yl]benzenesulfonamide
RL: PAC (Pharmacological activity); **THU (Therapeutic use);** BIOL (Biological study); USES (Uses)
(preparation of (hetero)cyclic compds. useful as calcium-activated potassium channel openers/activators)

RN 93014-16-5 CAPLUS
CN Benzenesulfonamide, 4-(2-methyl-4-phenyl-5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 169590-42-5 CAPLUS
CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RN 180200-68-4 CAPLUS
CN Benzenesulfonamide, 4-(4-cyclohexyl-2-methyl-5-oxazolyl)-2-fluoro- (9CI) (CA INDEX NAME)



RN 181695-72-7 CAPLUS
CN Benzenesulfonamide, 4-(5-methyl-3-phenyl-4-isoxazolyl)- (9CI) (CA INDEX NAME)



RN 198470-84-7 CAPLUS
CN Propanamide, N-[[4-(5-methyl-3-phenyl-4-isoxazolyl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 265114-23-6 CAPLUS
CN Benzenesulfonamide, 4-[4-chloro-5-(3-fluoro-4-methoxyphenyl)-1H-imidazol-1-yl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:678653 CAPLUS
DOCUMENT NUMBER: 139:207821
TITLE: Use of cyclooxygenase inhibitors and antimuscarinic agents for the treatment of incontinence
INVENTOR(S): Versi, Ebrahim
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003070233	A1	20030828	WO 2003-US4561	20030214
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003191172	A1	20031009	US 2003-368091	20030218

PRIORITY APPLN. INFO.: US 2002-357888P P 20020219

AB The invention provides a method for the use of a cyclooxygenase-2 inhibitor, alone or in combination with an antimuscarinic agent, for the treatment or prophylaxis of a **urinary incontinence** condition in a subject in need of such treatment or prevention, comprising administering to the subject an effective amount of the cyclooxygenase-2 inhibitor and, optionally, the antimuscarinic agent.

IT **169590-41-4**, Deracoxib **169590-42-5**, Celecoxib **180200-68-4**, JTE-522 **181695-72-7**, Valdecoxib **198470-84-7**, Parecoxib
RL: PAC (Pharmacological activity); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(cyclooxygenase inhibitors and antimuscarinic agents for treatment of

incontinence)

RN 169590-41-4 CAPLUS

CN Benzenesulfonamide, 4-[3-(difluoromethyl)-5-(3-fluoro-4-methoxyphenyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RN 169590-42-5 CAPLUS

CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RN 180200-68-4 CAPLUS

CN Benzenesulfonamide, 4-(4-cyclohexyl-2-methyl-5-oxazolyl)-2-fluoro- (9CI) (CA INDEX NAME)



RN 181695-72-7 CAPLUS
CN Benzenesulfonamide, 4-(5-methyl-3-phenyl-4-isoxazolyl)- (9CI) (CA INDEX NAME)



RN 198470-84-7 CAPLUS
CN Propanamide, N-[[4-(5-methyl-3-phenyl-4-isoxazolyl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:813909 CAPLUS
DOCUMENT NUMBER: 137:325416
TITLE: Preparation of substituted imidazoles/oxazoles/thiazoles as large conductance **calcium-activated K channel** openers
INVENTOR(S): Hongu, Mitsuya; Hosaka, Thoshihiro; Kashiwagi, Toshihiko; Kono, Rikako; Kobayashi, Hiroyuki
PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan
SOURCE: PCT Int. Appl., 302 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2002083111 A2 20021024 WO 2002-JP3723 20020415
WO 2002083111 A3 20040415
W: AE, AG, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CO, CR, CU, CZ, DM, DZ, EC, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, OM, PH, PL, RO, SG, SI, SK, TN, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.: JP 2001-116436 A 20010416
JP 2001-249671 A 20010820
OTHER SOURCE(S): MARPAT 137:325416
GI



I

AB The title compds. [I; X = NR4, O, S; R1, R2 = H, halo, CO2H, etc.; R3 = aryl, heterocyclyl, alkyl; R4 = H, alkyl], useful in the prophylaxis and/or treatment for **pollakiuria** or **urinary incontinence**, were prepared Thus, reacting 5-ethyl-2-iodo-4-(3-pyridyl)imidazole with 3-(hydroxymethyl)thiophene-2-boric acid in the presence of Pd(PPh3)4 and aqueous 2M Na2CO3 in dimethoxyethane afforded I.2HCl [X = NH; R1 = Et; R2 = 3-pyridyl; R3 = 3-(hydroxymethyl)thien-2-yl] which showed 100% inhibition time of 10-20 min in test on the rhythmic bladder contractions induced by substance P in anesthetized rats.

IT **473683-69-1P 473684-44-5P 473684-52-5P 473684-60-5P 473685-37-9P 473685-39-1P 473685-40-4P 473685-42-6P 473686-29-2P 473687-48-8P 473688-38-9P 473688-39-0P 473691-23-5P 473692-98-7P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazoles/oxazoles/thiazoles as large conductance **calcium-activated K channel** openers)

RN 473683-69-1 CAPLUS

CN 1H-Imidazole, 2-(4-fluorophenyl)-4-[4-(methylthio)phenyl]-5-propyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 473684-44-5 CAPLUS
CN 1H-Imidazole, 2-(3-fluorophenyl)-4-[(methylthio)methyl]-5-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 473684-52-5 CAPLUS
CN 1H-Imidazole, 2-(3-fluorophenyl)-4-[(methylsulfinyl)methyl]-5-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 473684-60-5 CAPLUS
CN 1H-Imidazole, 2-(4-fluorophenyl)-4-[(methylsulfonyl)methyl]-5-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 473685-37-9 CAPLUS
CN 1H-Imidazole, 2-(4-fluorophenyl)-4-[2-(methylsulfinyl)ethyl]-5-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 473685-39-1 CAPLUS
CN 1H-Imidazole, 4-[2-(ethylsulfinyl)ethyl]-2-(4-fluorophenyl)-5-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 473685-40-4 CAPLUS
CN 1H-Imidazole, 2-(4-chlorophenyl)-4-[(ethylsulfinyl)methyl]-5-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 473685-42-6 CAPLUS
CN 1H-Imidazole, 2-(4-chlorophenyl)-4-[2-(ethylsulfinyl)ethyl]-5-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 473686-29-2 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-fluorophenyl)-5-[2-[(methylsulfonyl)amino]phenyl]-, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 473687-48-8 CAPLUS
CN 4-Oxazoleacetic acid, 2-(4-fluorophenyl)-5-[2-[(methylsulfonyl)amino]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 473688-38-9 CAPLUS
CN Methanesulfonamide, N-[5-(4-chloro-3-fluorophenyl)-2-(4-fluorophenyl)-4-oxazolyl]-, sodium salt (9CI) (CA INDEX NAME)



● Na

RN 473688-39-0 CAPLUS
CN Thiourea, [[5-(4-chloro-3-fluorophenyl)-2-(4-fluorophenyl)-4-oxazolyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 473691-23-5 CAPLUS
CN 1H-Imidazole, 2-(4-fluorophenyl)-4-[(methylthio)methyl]-5-phenyl- (9CI) (CA INDEX NAME)



RN 473692-98-7 CAPLUS
CN 1H-Imidazole, 2-(4-fluorophenyl)-4-[(methylsulfinyl)methyl]-5-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L11 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:655085 CAPLUS
DOCUMENT NUMBER: 137:179926
TITLE: Use of selective cyclooxygenase 2 (COX-2) inhibitors for the treatment of **urinary incontinence**
INVENTOR(S): Leonardi, Amedeo; Testa, Rodolfo; Guarneri, Luciano
PATENT ASSIGNEE(S): Recordati S.A., Chemical and Pharmaceutical Company, Switz.
SOURCE: U.S., 19 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6440963	B1	20020827	US 2001-969538	20011001
WO 2002080927	A1	20021017	WO 2002-EP3850	20020405
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1381369	A1	20040121	EP 2002-722290	20020405
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2002008694	A	20040330	BR 2002-8694	20020405
NO 2003004473	A	20031205	NO 2003-4473	20031006

PRIORITY APPLN. INFO.: IT 2001-MI733 A 20010405
WO 2002-EP3850 W 20020405
OTHER SOURCE(S): MARPAT 137:179926

AB The treatment of neuromuscular dysfunction of the lower urinary tract by compds. which selectively inhibit the COX-2 isoenzyme is described. The compds. concerned inhibit the COX-2 isoenzyme with a potency at least 10-fold, and preferably at least 100-fold, greater than their potency on the COX-1 isoenzyme.

IT **169590-42-5 181695-72-7 198470-84-7**
RL: PAC (Pharmacological activity); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(cyclooxygenase 2 inhibitors for treatment of **urinary**

incontinence)

RN 169590-42-5 CAPLUS

CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RN 181695-72-7 CAPLUS

CN Benzenesulfonamide, 4-(5-methyl-3-phenyl-4-isoxazolyl)- (9CI) (CA INDEX NAME)



RN 198470-84-7 CAPLUS

CN Propanamide, N-[[4-(5-methyl-3-phenyl-4-isoxazolyl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 59 THERE ARE 59 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> d his

     (FILE 'HOME' ENTERED AT 08:57:55 ON 07 MAY 2004)

     FILE 'REGISTRY' ENTERED AT 08:58:10 ON 07 MAY 2004
L1              STRUCTURE UPLOADED
L2            4 S L1
L3       473612 S 3/NR AND 2-3/N AND 0-5/O AND 0-1/S
L4            5 S L1 SAM SUB=L3
L5         4113 S L1 FULL SUB=L3

     FILE 'CAPLUS' ENTERED AT 09:04:53 ON 07 MAY 2004
L6         1011 S L5/THU
L7          105 S CALCIUM ACTIVATED K CHANNEL?
L8            1 S L6 AND L7
L9          930 S POLLAKIURIA OR URINARY INCONTINENCE
L10           4 S L6 AND L9
L11           4 S L8 OR L10

=> d l1
L1 HAS NO ANSWERS
L1              STR
```




```
G1 X,SO2


Structure attributes must be viewed using STN Express query preparation.

=>
```

PALM INTRANET

Day : Friday
Date: 5/7/2004
Time: 07:53:48

Inventor Name Search Result

Your Search was:

Last Name = KONO
First Name = RIKAKO

Application#	Patent#	Status	Date Filed	Title	Inventor Name 3
60411749	Not Issued	020	09/19/2002	LARGE CONDUCTANCE CALCIUM-ACTIVATED K CHANNEL OPENER	KONO, RIKAKO
10665528	Not Issued	071	09/22/2003	LARGE CONDUCTANCE CALCIUM-ACTIVATED K CHANNEL OPENER	KONO, RIKAKO
10474850	Not Issued	020	02/10/2004	LARGE CONDUCTANCE CALCIUM-ACTIVATED K CHANNEL OPENER	KONO, RIKAKO

Inventor Search Completed: No Records to Display.

Search Another: Inventor

Last Name Kono **First Name** Rikako

Search

To go back use Back button on your browser toolbar.

Back to PALM | ASSIGNMENT | OASIS | Home page